The Journal of Korean Medicine (대한한의학회지)

The Society of Korean Medicine (대한한의학회)
권호 표지

Effect of negative therapy at back meridian points on blood gas components and immune functions in male college students

배부(背部) 경혈(經穴)에 부항요법(附缸療法) 시술(施術)이 남자대학생(男子大學生)의 면역기능(免疫機能)에 미치는 영향(影響)

  • 오재근 (한국체육대학교 건강관리학과) ;
  • 김성수 (경희대학교 한의과대학)
  • Published : 1999.03.30
Download PDF
⟨ Previous Next ⟩

Abstract

To investigate the effects of negative therapy at back meridian points on blood gas components and immune functions in male college students, this study was conducted on treatment types(abdomen group and back group) at three sampling times (before, post-2 wks and post-4 wks) by using $2{\times}3$ factoral design. Blood gas $components(pH,\;PCO_2,\;PO_2,\;HCO_3^-,\;O_2SAT,\;BE)$, red blood cell, hematocrit, hemoglobin, white blood cell and subsets(neutrophil, basophil, eosinophil. lymphocyte, monocyte), total T cells, helper T cells, suppressor T cells, Th/Ts ratio, total B cells, serum immunoglobulin levels (IgG, IgA, IgM, IgD, IgE), Cytokines(Interlukin$-1{\beta}$, -2, -4, 2 receptor, -6 and ${\gamma}$-interferon), NK cells were measured. Collected with data were analyzed statistically by repealed measured ANOVA. The pattern of change between two groups for hematocrit, hemoglobin, suppressor T cells, interleukin-6, ${\gamma}-interferon$, NK cells at post-2 weeks and BE, lymphocyte, basophil at post-4 weeks was significantly different(p<0.05) And also the pattern of change over time for ${HCO_3}^-$(2 wks vs 4 wks), WBC, neutrophil, lymphocyte(0 wks vs 2 wks and 2 wks vs 4 wks) was significantly different(p<0.05). In summary, these data suggest that negative therapy at back meridian points had an effect on blood gas components and immune functions in male college students because practicing negative therapy at back meridian points was not associated with changes of all blood gas components and immune factors but associated with changes of BE, hematocrit, hemoglobin, WBC. neutrophil, lymphocyte, interleukin-6. ${\gamma}-interferon$, NK cells.

Keywords

References

  1. 基本免疫學 文希柱;權赫한
  2. 免疫學入門 金周德(外)
  3. 임상병리파일 이귀녕;이종순
  4. 동의재활의학과학 全國韓醫科大學再活醫學敎室
  5. 慶熙大學校大學院 碩士學位論文 附缸 施術에 의해 배출된 체표 GAS 分析에 關한 硏究 김길수
  6. 대한미생물학회지 v.26 IL-2, IFN-r 및 poly(A) poly(U)에 의한 림프구의 Crytococcus neoformans 증식 억제작용의 항진. 박영민;하대유;박병숙
  7. 新中醫 v.6 正邪論新釋 嚴宗正
  8. Cancer. v.38 Immunocompetent cell in patients with malignant disease. I. The lack of naturally occuring killer cell activity in the unfractionated circulating lymphocytes from patients with chronic lymphocytic leukemia. Behelak, Y.;Banerjee, D.;Richter, M.
  9. Cell Immunol v.49 Purified human interferon has more potent anticellular activity than fibroblast or leukocyte interferon. Blalock, J.E.;Geordiades, J.A.;Langford, M.P.;Johnson, H.M.
  10. Clin Immunol Immunopathol interferon: Pleiotropic cellular modulators. Borben, E.C.
  11. J Leukoc Biol v.57 IL-15, a novel T cell growth factor that shares activaties and geceptor components with IL-2. Giri, J.G.;Anderson, D.M.;Kumaki, S.;Park, L.S.;Grabstein, K.H.;Cosman, D.
  12. Annu. Tev. Immunol. v.1 Regulation of B cell growth and differentiation by soluble factors. Howard, M.;Paul, W.E.
  13. J. Immunol. v.142 Bacterial Iipopolysacchride and inflammatory mediators augment IL-6 secretion by human endothelial cells. Jirik, F.R.;Podor, T.J.;Hirano, T.;Kishimoto, T.;Loskuioff, D.J.;Carson, D.A.;Lotz, M.
  14. Annu. Tev. Immunol. v.3 Factors affecting B-cell growth and differentiation. Kishimoto, T.
  15. J. Clin. Immunol. v.7 B cell stimulatory Factors(BSF'S): molecular structure, biolgical functions and regulation of expression. Kishimoto, T.
  16. J. Nat. Cancer Inst. v.56 The nonselective cytotoxic cell(N cell). Kiuchi, M.;Takasugi, M.
  17. Semen Oncol v.13 Interferons and interferon inducers in cancer treatment. Krown, S.E.
  18. Lancet. v.1 Spontaneous cytotoxic activity as a test of human lymphocytes function. Matthaus, N.;Maclaurin, B.P.
  19. J. Nat. Cancer Inst. v.51 Immunopitentiation with BCG II, Modulation of the response to sheep red blood cells, Miller, T.E.(et al)
  20. Cell. Immunol. v.130 Distinctive features in the production of IL-6 by human T cells. Ming, J.E.;Angela, G.P.
  21. Adv Immunol v.55 Receptors for transforming growth factor-${\beta}$. Miyazono, K.;Dijke, P.J.;Ichujuo, H.;Heldin, C.H.
  22. Adv Immunol. v.56 Pwoperties and functions of interleukin-10. Mossman, T.R.
  23. J. Nat. Cancer Inst. v.53 Cellular microcytotoxicity in human tumor systems: Analysis of results. Oldham, R.K.;Djeu, J.Y.;Cannon, G.B.;Siwarski, D.;Herberman, R.B.
  24. Clin. Exp. Immunol. v.21 Cytotoxicity of lymphocytes from healthy subject and from melanoma patients against cultured melanoma cells Payie-Fisher, J.;Kourilski, F.M.;Picard, F.;Banzet, P.;Puissant, A.
  25. J. Immunol. v.116 Spontaneous cytotoxicity(CMC) of normal human lymphocytes against human melanoma cell line : A phenomenon due to a lymphotoxin like mediator. Petet, H.H.;Eifes, R.F.;Kalden, J.R.
  26. J. Exp. Med. v.173 Cytokine-induced production of human B lymphocytes triggered through thier CD40 antigen. Rousseet, F.;Garcia, E.;Banvhereau, J.
  27. Science. v.235 T and B cell differentiation factor, BSF-2, are identical. Sehgal, P.B.;May, L.T;Tamm, I.
  28. J Leukoc Biol v.52 Regulatory role of cytokines in IgE-mediated allergy. Tan, H.P.;Lebeck, L.K.;Nehlsen-Cannarella, S.L.
  29. Science. v.239 Monocyte-derved human B-cell growth facter identified as inteferon-${\beta}$2(BSF-2, IL-6). Tosato, G.;Seammon, K.B.;Goldman, N.D.;Sehgal, P.B.;May, L.T.;Wsshington, G.C.;Jones, K.D.;Pike, S.E.
  30. Immunol Today v.6 Immune interferon: a pleiotropic lymphokine with multiple effects. Trinchieri, G.;Perussia, B.
  31. Eur. J. Immunol. v.19 Recombinant interleukin (IL)2-induced human B Cell diffetentiation is mediated by autocrine IL-6. Xia, X.;Lee, H.K.;Clark, S.C.;Choi, Y.S.
  32. 生理學 金正鎭